Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Stopped early · Phase 1/Phase 2
Conditions studied: Non-Hodgkin's Lymphoma
In brief
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Key facts
- Study ID
- NCT00057447
- Run by
- InterMune
- People needed
- 24
- Starts
- 2003-03-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2007-11-01
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Intermune Inc — Brisbane, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.